SAN FRANCISCO--(BUSINESS WIRE)--SmithRx, a transparent and 100% pass-through pharmacy benefits manager (PBM), today introduced a new PBM evaluation methodology – cost-based evaluation – optimized for lowering pharmacy benefits costs. Cost-based evaluation is detailed in SmithRx’s PBM Evaluation Guide, a comprehensive industry analysis unveiled today that offers an alternative path forward for pharmacy benefits management.

旧金山--（商业新闻短讯）--SmithRx是一家透明且100%通过的药房福利经理（PBM），今天推出了一种新的PBM评估方法-基于成本的评估-针对降低药房福利成本进行了优化。SmithRx的PBM评估指南中详细介绍了基于成本的评估，该指南是今天发布的一项综合行业分析，为药房福利管理提供了另一条前进道路。

Alongside the guide, the company also released new cost-savings data, which underscores how SmithRx’s cost-focused strategy results in a meaningful reduction in drug spend for employers – setting a new standard in the PBM industry..

除了指南之外，该公司还发布了新的成本节约数据，该数据强调了SmithRx以成本为中心的战略如何有效减少雇主的药物支出，从而为PBM行业树立了新标准。。

SmithRx’s strategy is focused on finding the lowest net cost of prescription medications for its employer clients, rather than the common industry tactic of optimizing for higher discounts. While both may seem like viable paths to cost reduction, SmithRx’s data demonstrates how optimizing for lower net cost over discounts guarantees results in significantly lower spend on pharmacy benefits.

SmithRx的战略重点是为其雇主客户找到最低的处方药净成本，而不是优化更高折扣的常见行业策略。虽然这两种方法似乎都是降低成本的可行途径，但SmithRx的数据表明，优化净成本而不是折扣保证可以显着降低药房福利支出。

Paired with the company’s 100% pass-through and transparent business model, employers see significant cost savings, helping them lower healthcare costs for themselves and their employees..

再加上公司百分之百的通关和透明的商业模式，雇主看到了巨大的成本节约，帮助他们降低了自己和员工的医疗保健成本。。

SmithRx’s proprietary data shows the following impact:

SmithRx的专有数据显示了以下影响：

$113.7M in new annualized savings year-to-date from Connect 360 programs across the SmithRx customer base, equating to an average $24 cost savings per member per month (PMPM);

SmithRx客户群中的Connect 360计划迄今为止每年新增节省1.137亿美元，相当于每个会员每月平均节省24美元（PMPM）；

20-40% lower average PMPM compared to other pass-through and traditional PBMs;

与其他直通和传统PBM相比，平均PMPM降低20-40%；

$31M in new annualized savings year-to-date across customers that have elected to save on autoimmune drugs, some of the costliest medications on the market today.

今年迄今为止，选择节省自身免疫药物（目前市场上价格最高的一些药物）的客户每年新增节省3100万美元。

Since their creation in the 1960s, three primary PBMs have come to dominate the industry – supported by large-scale vertical integration within the healthcare system. Now, CVS Caremark (owned by CVS Health), OptumRx (owned by UnitedHealthcare Group), and Express Scripts (owned by Cigna) control over 80% of the market share, and leverage opaque pricing structures, restricted access to information, and preferred pricing at their owned pharmacies to maximize profits.

自20世纪60年代创立以来，三家主要的PBM已在该行业占据主导地位，并得到了医疗保健系统内大规模垂直整合的支持。现在，CVS Caremark（由CVS Health拥有）、OptumRx（由UnitedHealthcare Group拥有）和Express Scripts（由Cigna拥有）控制了80%以上的市场份额，并利用不透明的定价结构、限制信息获取以及自有药店的首选定价来实现利润最大化。

For small businesses and their employees, this escalation has led to rising drug costs, inaccessible medications, and severe ramifications for healthcare spending..

对于小企业及其员工来说，这种升级导致药品成本上升，无法获得药物，以及对医疗保健支出的严重影响。。

The benefits of a modern PBM that offers a radically transparent, pass-through approach are outlined in SmithRx’s new PBM Evaluation Guide, designed to educate and support benefits brokers, HR professionals, and consultants as they determine pharmacy benefits for their clients or employees. The guide introduces the use of a cost-based evaluation method in making a PBM selection to ensure a proper review of PBM options, and is the first in a series of resources created to showcase the fundamental disadvantages of the legacy PBM business model and how pass-through structures methods can improve drug spending for small businesses in America..

SmithRx新的PBM评估指南概述了现代PBM的好处，该方法提供了一种完全透明的传递方法，旨在教育和支持经纪人、人力资源专业人员和顾问在确定其客户或员工的药房福利时的福利。该指南介绍了在进行PBM选择时使用基于成本的评估方法，以确保正确审查PBM选项，并且是为展示传统PBM商业模式的基本缺点以及传递结构方法如何改善美国小企业的药品支出而创建的一系列资源中的第一个。。

“The PBM industry is at a crossroads today, as light is finally being shed on the lack of transparency and fairness in traditional business models,” said Jake Frenz, founder and CEO of SmithRx. “At SmithRx, our data shows how removing tactics like spread pricing and rebate take – and focusing instead on connecting patients to the lowest cost source of supply – leads to widespread cost savings for our customers and their employees.

SmithRx创始人兼首席执行官杰克·弗伦茨（JakeFrenz）表示：“PBM行业如今正处于十字路口，传统商业模式缺乏透明度和公平性的问题终于被曝光。”。“在SmithRx，我们的数据显示，取消差价定价和返利等策略，转而将重点放在将患者与最低成本的供应源联系起来，可以为我们的客户及其员工带来广泛的成本节约。

It’s clear that it is possible to create an ethical PBM industry, one that has the best interest of patients at heart. But it’s critical that we empower those willing to divest from the status quo with the information, context, and support they need to make informed decisions.”.

很明显，有可能创建一个合乎道德的PBM行业，一个以患者的最大利益为核心的行业。但至关重要的是，我们要为那些愿意摆脱现状的人提供他们做出明智决策所需的信息、背景和支持。”。

SmithRx’s PBM Evaluation Guide is available to download here. To learn more about the company’s transparent, pass-through business model and cost-based evaluation, visit www.smithrx.com.

。要了解更多有关公司透明、贯穿始终的商业模式和基于成本的评估的信息，请访问www.smithrx.com。

About SmithRx

关于SmithRx

SmithRx is working to reduce the complexity and cost of pharmacy benefits by building a new type of pharmacy benefits manager (PBM) committed to transparency that’s aligned with employers and patients. By combining advanced technology, a member-centric approach, and innovative cost savings programs, we're making prescriptions more affordable and delivering valuable transparency and savings to main street businesses..

SmithRx正在通过建立一种新型的药房福利管理器（PBM）来降低药房福利的复杂性和成本，该管理器致力于与雇主和患者保持一致的透明度。通过结合先进技术、以会员为中心的方法和创新的成本节约计划，我们正在使处方更实惠，并为主要街道企业提供有价值的透明度和节约。。